Landscapes / Companies
argenx not checked
FollowEvery new trial, moved date and filing, and a Monday email
Drugs
6
in active trials · 9 in all
Trials
35 active
73 since 2021
Drugs6
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Approved | Mar 2027Phase 2/3 trial completes | |||
| Next date | Mar 2027 · Phase 2/3 trial completes | ||||
| Also tested for | Generalized Myasthenia Gravis, gMG and 32 more | ||||
| Open drug page | |||||
Artificial immunoglobulin |
Phase 3 | Nov 2026soonPhase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Multifocal Motor Neuropathy (MMN), Chronic Inflammatory Demyelinating Polyneuropathy and 16 more | ||||
| Open drug page | |||||
Artificial immunoglobulin |
Phase 3 | 28 May 2029Phase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | 28 May 2029 · Phase 2 trial completes | ||||
| Also tested for | Congenital Myasthenic Syndrome, CMS and 1 more | ||||
| Open drug page | |||||
EFG PH20not checked |
— |
Phase 2 | Mar 2027Phase 2 trial completes | ||
| Next date | Mar 2027 · Phase 2 trial completes | ||||
| Also tested for | Systemic Sclerosis (SSc) | ||||
| Open drug page | |||||
— |
Phase 2 | 29 Oct 2029Phase 2 trial completes | |||
| Next date | 29 Oct 2029 · Phase 2 trial completes | ||||
| Also tested for | Immunoglobulin A Nephropathy (IgAN) | ||||
| Open drug page | |||||
— |
Phase 1 | 31 Dec 2026Phase 1 trial completes | |||
| Next date | 31 Dec 2026 · Phase 1 trial completes | ||||
| Open drug page | |||||
About
- No active trial
- ARGX-109, ARGX-213, efgartigimod PH20 in stage B
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021